Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Inhaled PUR0200 Formulations vs Reference in Healthy Adults
NCT02671825Phase 1Completed
- Sponsor
- Pulmatrix, Inc.
- Start
- Jan 2016
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Pulmatrix, Inc. Primary endpoints: Area Under the Plasma Concentration versus Time Curve at 8 hours and Peak Plasma Concentration at 8 hours. Started Jan 2016; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02671825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671825.